Search
Dicoumarol
go.drugbank.com/drugs/DB00266ApprovedDicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K. … In addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesSynonyms: di-(4-hydroxy-3-coumarinyl)methaneDoxorubicin
go.drugbank.com/drugs/DB00997ApprovedInvestigationalDoxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970. Although they both have aglyconic and sugar moieties, doxor...
Categories: P-glycoprotein inducers, P-glycoprotein inhibitorsProducts: DOXOLEM RU, DOXORUBICIN AU 2MG/ML 10MGEnprofylline
go.drugbank.com/drugs/DB00824ApprovedWithdrawnEnprofylline is a derivative of theophylline which shares bronchodilator properties. Enprofylline is used in asthma, chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and ...
Categories: Purinergic P1 Receptor AntagonistsLifitegrast
go.drugbank.com/drugs/DB11611ApprovedInvestigationalLifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through...
Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme InhibitorsLiothyronine
go.drugbank.com/drugs/DB00279ApprovedInvestigationalVet approvedLiothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine w...
Categories: P-glycoprotein inducersZilucoplan
go.drugbank.com/drugs/DB15636ApprovedInvestigational[L48701] It was also later approved by the EMA on December 4, 2023, as an add-on treatment for the same condition.[L49131] In July 2024, it was approved by Health Canada for the same indication.
Atogepant
go.drugbank.com/drugs/DB16098ApprovedInvestigational[propranolol]), all of which can be associated with significant adverse effects. … Atogepant is an oral antagonist of calcitonin gene-related peptide (CGRP) receptors indicated for the prevention of episodic migraine headaches.
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesCintredekin besudotox
go.drugbank.com/drugs/DB05305InvestigationalCintredekin besudotox is made from a human protein, Interleukin 13 (IL13), linked to a bacterial toxin, _Pseudomonas exotoxin_ (PE). The IL13 portion binds to receptors on the tumor.
X-376
go.drugbank.com/drugs/DB13104InvestigationalX-376 is an inhibitor of the anaplastic lymphoma kinase (ALK) which can penetrate the blood brain barrier.[A265085]
Bebtelovimab
go.drugbank.com/drugs/DB16755ApprovedWithdrawn[L43827] On November 30, 2022, the EUA for bebtelovimab was officially withdrawn due to a lack of efficacy against Omicron subvariants, therefore bebtelovimab is no longer authorized for emergency use … [L40328] Bebtelovimab was issued an emergency use authorization (EUA) by the FDA on February 11, 2022, for the treatment of mild-to-moderate COVID-19 in select patients.